Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 11, 2025 20:40 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced the pricing of an underwritten public...
November 11, 2025 16:00 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that it has commenced an underwritten...
November 07, 2025 08:00 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines...
November 05, 2025 07:00 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study;...
September 03, 2025 07:00 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational...
August 12, 2025 07:00 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type...
June 16, 2025 09:00 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration...
May 19, 2025 08:00 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines...
May 14, 2025 07:00 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1...
March 24, 2025 07:00 ET | Source: Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1...